1. Home
  2. AHRT vs STTK Comparison

AHRT vs STTK Comparison

Compare AHRT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AHRT

AH Realty Trust Inc. Common Stock

N/A

Current Price

$6.48

Market Cap

455.6M

Sector

Finance

ML Signal

N/A

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$7.02

Market Cap

528.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AHRT
STTK
Founded
1979
2016
Country
United States
United States
Employees
98
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
455.6M
528.3M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
AHRT
STTK
Price
$6.48
$7.02
Analyst Decision
Hold
Buy
Analyst Count
1
7
Target Price
$7.00
$10.00
AVG Volume (30 Days)
620.4K
471.8K
Earning Date
05-04-2026
05-01-2026
Dividend Yield
9.30%
N/A
EPS Growth
N/A
53.02
EPS
N/A
N/A
Revenue
N/A
$1,000,000.00
Revenue This Year
$854.92
N/A
Revenue Next Year
$11.36
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.13
$0.71
52 Week High
$6.50
$8.33

Technical Indicators

Market Signals
Indicator
AHRT
STTK
Relative Strength Index (RSI) 65.90 52.83
Support Level $5.93 $1.85
Resistance Level N/A $7.68
Average True Range (ATR) 0.16 0.59
MACD 0.04 -0.13
Stochastic Oscillator 98.28 50.46

Price Performance

Historical Comparison
AHRT
STTK

About AHRT AH Realty Trust Inc. Common Stock

AH Realty Trust Inc is a real estate investment trust (REIT). It owns, operates, and acquires high-quality properties across the Mid-Atlantic and Southeast, creating lasting value for investors, partners, clients, tenants, and communities. The group focuses on operating and acquiring high-quality, well-positioned assets with growth potential and delivering long-term value for shareholders. Its portfolio includes Harbor Point, Southern Post, The Interlock, and Others.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: